AstraZeneca CEO buys 60,000 shares at £121

AstraZeneca’s CEO Pascal Soriot disclosed a purchase of 60,000 ordinary shares on September 14, 2026.

Rhea-AI Filing Summary

AstraZeneca PLC (AZN) reports that Chief Executive Officer Pascal Soriot purchased additional equity in the company. On September 14, 2026, Soriot bought 60,000 AstraZeneca Ordinary Shares with a nominal value of US$0.25 each at a price of £121.02 per share on the LON market. The transaction is disclosed as a purchase by a Person Discharging Managerial Responsibilities in accordance with the EU Market Abuse Regulation as it forms part of UK law.

Key Figures

Shares purchased: 60,000 shares Purchase price per share: £121.02 per share Nominal value per Ordinary Share: US$0.25 per share +1 more

4 metrics

Shares purchased 60,000 shares Ordinary Shares acquired by CEO Pascal Soriot on September 14, 2026

Purchase price per share £121.02 per share Price paid for AstraZeneca PLC Ordinary Shares in the CEO’s transaction

Nominal value per Ordinary Share US$0.25 per share Par value of AstraZeneca PLC Ordinary Shares referenced in the disclosure

Transaction date September 14, 2026 Date of CEO Pascal Soriot’s purchase of AstraZeneca PLC Ordinary Shares

Key Terms

Person Discharging Managerial Responsibilities, EU Market Abuse Regulation, Ordinary Shares, LEI

4 terms

Person Discharging Managerial Responsibilities regulatory

"Transaction by Person Discharging Managerial Responsibilities AstraZeneca PLC"

A person discharging managerial responsibilities is an individual who holds a senior role with authority to make or influence a company’s strategic or operational decisions, such as executives, board members, or other top managers. Investors care because these people often have access to confidential information and their buying or selling of company shares must be disclosed—like a referee who knows the score before the crowd, their actions can signal important, non-public insights about a company's prospects.

EU Market Abuse Regulation regulatory

"notification, made in accordance with the requirements of the EU Market Abuse Regulation"

A set of EU-wide rules that prevent cheating in financial markets by banning insider trading, market manipulation, and misleading disclosure; it also requires timely public release of key company information so everyone can play on a level field. For investors, it reduces the risk that prices are driven by secret deals or false signals, making markets fairer and more reliable for deciding when to buy or sell — like referees enforcing fair play in a game.

Ordinary Shares financial

"purchased 60,000 of the Company's ordinary shares of $0.25 each (Ordinary Shares)"

Ordinary shares are a type of ownership stake in a company, giving shareholders a right to participate in the company’s profits and decision-making through voting. They are similar to owning a piece of a business, and their value can rise or fall based on the company's performance. Investors buy ordinary shares to potentially earn dividends and benefit from the company's growth over time.

LEI financial

"LEI | PY6ZZQWO2IZFZC3IOL08"

A Legal Entity Identifier (LEI) is a unique 20-character code assigned to a company or organization that participates in financial markets, like a corporate passport number. It helps investors and regulators unambiguously identify counterparties across databases and transactions, reducing confusion much like using a vehicle identification number to track a car’s history; clearer identification improves transparency, risk monitoring, and regulatory reporting.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider share transaction did AstraZeneca (AZN) disclose in this 6-K?

AstraZeneca disclosed that CEO Pascal Soriot purchased 60,000 Ordinary Shares of AstraZeneca PLC on September 14, 2026 at a price of £121.02 per share.

Who at AstraZeneca (AZN) made the reported share purchase and in what role?

The reported share purchase was made by Pascal Soriot, who is identified as Executive Director and Chief Executive Officer of AstraZeneca PLC and a Person Discharging Managerial Responsibilities.

At what price were the AstraZeneca (AZN) shares bought in the CEO’s transaction?

Pascal Soriot bought the AstraZeneca PLC Ordinary Shares at a price of £121.02 per share, according to the disclosed transaction details.

On what date did the AstraZeneca (AZN) CEO’s share purchase occur and where was it executed?

The share purchase took place on September 14, 2026 and was executed on the LON market, as stated in the transaction disclosure.

What type of securities did the AstraZeneca (AZN) CEO acquire in this transaction?

Pascal Soriot acquired Ordinary Shares of US$0.25 each in AstraZeneca PLC, described as AstraZeneca PLC Ordinary Shares of US$0.25 in the notification.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/18/2026 - 06:34 AM Accepted by SEC EDGAR 09/18/2026 - 06:33 AM Learn about SEC filing dates

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of

the Securities Exchange Act of 1934

For the month of September 2026 

Commission File Number: 001-11960

AstraZeneca PLC

1 Francis Crick Avenue

Cambridge Biomedical Campus

Cambridge CB2 0AA

United Kingdom

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F X Form 40-F __

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ______

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes __ No X

If “Yes” is marked, indicate below the file number assigned to the Registrant in connection with Rule 12g3-2(b): 82-_____________

AstraZeneca PLC

INDEX TO EXHIBITS

1.

Director/PDMR Shareholding

 18 September 2026

Transaction by Person Discharging Managerial Responsibilities

AstraZeneca PLC (the Company) announces that it was notified on 16 September 2026 that Pascal Soriot, Chief Executive Officer of the Company, purchased 60,000 of the Company's ordinary shares of $0.25 each (Ordinary Shares) on 14 September 2026, as set out below.

PDMR	Position	Nature of the transaction	Date	Quantity	Price
Pascal Soriot	Executive Director and Chief Executive Officer	Purchase of Ordinary Shares	14/09/2026	60,000	GB£121.02

Further details are set out in the attached notification, made in accordance with the requirements of the EU Market Abuse Regulation (as it forms part of UK law pursuant to the European Union (Withdrawal) Act 2018).

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Pascal Soriot
2	Reason for the notification
a)	Position/status	Executive Director and Chief Executive Officer
b)	Initial notification /Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	AstraZeneca PLC
b)	LEI	PY6ZZQWO2IZFZC3IOL08
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument Identification code	Ordinary Shares of US$0.25 each in AstraZeneca PLC GB0009895292
b)	Nature of the transaction	Purchase of AstraZeneca PLC Ordinary Shares of US$0.25
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		£121.02	60,000
d)	Aggregated information - Aggregated volume - Price	Not applicable - single transaction
e)	Date of the transaction	14 September 2026
f)	Place of the transaction	LON

AstraZeneca

AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca's innovative medicines are sold in more than 125 countries and used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Social Media @AstraZeneca.

Contacts

For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here.

Matthew Bowden

Company Secretary

AstraZeneca PLC

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

AstraZeneca PLC

Date: 18 September 2026

By: /s/ Matthew Bowden

Name: Matthew Bowden

Title: Company Secretary